keyword
MENU ▼
Read by QxMD icon Read
search

Elderly, chemotherapy, lung cancer

keyword
https://www.readbyqxmd.com/read/28631097/phase-ii-study-of-amrubicin-monotherapy-in-elderly-or-poor-risk-patients-with-extensive-disease-of-small-cell-lung-cancer
#1
Satoshi Igawa, Sakiko Otani, Shinichiro Ryuge, Tomoya Fukui, Yoshiro Nakahara, Yasuhiro Hiyoshi, Mikiko Ishihara, Seiichiro Kusuhara, Shinya Harada, Hisashi Mitsufuji, Masaru Kubota, Jiichiro Sasaki, Noriyuki Masuda
Background Previous study indicated that an optional anti-cancer drug for the treatment of small-cell lung cancer (SCLC) is amrubicin. However, no prospective studies have evaluated amrubicin in chemo-naive elderly or poor-risk patients with SCLC. Therefore, this study aimed to evaluate the efficacy of amrubicin as first-line chemotherapy for elderly or poor-risk patients with extensive-disease SCLC (ES-SCLC). Methods Patients with chemotherapy-naive ES-SCLC received multiple cycles of 40 mg/m(2) amrubicin for 3 consecutive days every 21 days...
June 20, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28625635/trends-in-treatment-and-relative-survival-among-non-small-cell-lung-cancer-patients-in-the-netherlands-1990-2014-disparities-between-younger-and-older-patients
#2
Elisabeth J Driessen, Mieke J Aarts, Gerbern P Bootsma, Judith G van Loon, Maryska L Janssen-Heijnen
BACKGROUND: This study aimed to describe trends over time regarding disparities in treatment and relative survival (RS) between younger and older patients with non-small cell lung cancer (NSCLC). METHODS: All patients diagnosed with pathologically verified NSCLC in 1990-2014 were included from the Netherlands Cancer Registry (n=187,315). Treatment and RS (adjusted for sex, histology and treatment) were analyzed according to age group (<70 years versus ≥70 years), stage and five-year period of diagnosis...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28616905/-clinicopathological-features-diagnoses-and-treatments-of-6-458-lung-cancer-patients
#3
Lei Li, Dan Liu, Li Zhang, Ping Zhou, Juan Song, Yue Cheng, He Yu, Shuang Zhao, Wei-Min Li
OBJECTIVES: Lung cancer is the leading cause of cancer-related death on a global scale. This study aimed to review the clinicopathological featuresof primary lung cancer and the practice in diagnoses and treatments. METHODS: Medical record of patients diagnosed with primary lung cancer in West China Hospital of Sichuan University from 2008 to 2014 were retrospectively reviewed. Clinical characteristics of the patients, including pathological type, age, gender, and TNM stage were analyzed...
May 2017: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28592139/adjuvant-chemotherapy-for-elderly-patients-with-non-small-cell-lung-cancer
#4
Keiji Yamanashi, Norihito Okumura, Yoshiharu Yamamoto, Ayuko Takahashi, Takashi Nakashima, Tomoaki Matsuoka, Kotaro Kameyama
Background Adjuvant chemotherapy after complete surgical resection is currently the standard of care for patients with stage IB, II, or IIIA non-small-cell lung cancer. However, the generalizability of this treatment to elderly patients is controversial. We investigated the effects of adjuvant chemotherapy in patients aged over 75 years with stage IB-IIIA non-small-cell lung cancer. Methods We retrospectively analyzed 246 consecutive patients aged over 75 years with stage IB-IIIA non-small-cell lung cancer who underwent standard lung cancer surgery between January 2001 and December 2015...
January 1, 2017: Asian Cardiovascular & Thoracic Annals
https://www.readbyqxmd.com/read/28590338/surgery-as-part-of-radical-treatment-for-malignant-pleural-mesothelioma
#5
David A Waller, Sara Tenconi
PURPOSE OF REVIEW: To review the latest developments in surgery for malignant pleural mesothelioma both in patient selection, surgical technique, and strategy. RECENT FINDINGS: The International Association for the Study of Lung Cancer mesothelioma staging project has produced data to inform the 8th tumour node metastasis revision. The difficulty in clinical N staging and clinical T staging are highlighted and the importance of tumour volume is recognized. New imaging techniques can be utilized to assess tumour volume...
July 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/28551663/safety-of-first-line-chemotherapy-with-metronomic-single-agent-oral-vinorelbine-in-elderly-patients-with-nsclc
#6
Manlio Mencoboni, Rosa Angela Filiberti, Paola Taveggia, Lisette Del Corso, Alessandro Del Conte, Maria Grazia Covesnon, Cheti Puccetti, Sara Donati, Laura Auriati, Domenico Amoroso, Andrea Camerini
BACKGROUND/AIM: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points. PATIENTS AND METHODS: Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28549414/phase-i-ii-study-of-induction-chemotherapy-using-carboplatin-plus-irinotecan-and-sequential-thoracic-radiotherapy-trt-for-elderly-patients-with-limited-disease-small-cell-lung-cancer-ld-sclc-torg-0604
#7
Yuki Misumi, Hiroaki Okamoto, Jiichiro Sasaki, Noriyuki Masuda, Mari Ishii, Tsuneo Shimokawa, Yukio Hosomi, Yusuke Okuma, Makoto Nagamata, Takashi Ogura, Terufumi Kato, Masafumi Sata, Sakiko Otani, Akira Takakura, Koichi Minato, Yosuke Miura, Takuma Yokoyama, Saori Takata, Katsuhiko Naoki, Koshiro Watanabe
BACKGROUND: The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing of TRT combined with chemotherapy has not been fully evaluated. METHODS: Patients aged > 70 years with untreated, measurable, LD-SCLC, performance status (PS) 0-2, and adequate organ function were eligible. Treatment consisted of induction with carboplatin on day 1 and irinotecan on days 1 and 8, every 21 days for 4 cycles, and sequential TRT (54Gy in 27 fractions)...
May 26, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28527959/systemic-treatment-patterns-with-advanced-or-recurrent-non-small-cell-lung-cancer-in-japan-a-retrospective-hospital-administrative-database-study
#8
Feng Wang, Sari Mishina, Shinji Takai, T Kim Le, Kenya Ochi, Kotaro Funato, Shozo Matsuoka, Yuichiro Ohe
PURPOSE: Data on the treatment of non-small cell lung cancer (NSCLC) in real-world clinical practice in Japan are limited. This large-scale, retrospective cohort study examined data on patients' characteristics and systemic therapies for advanced or recurrent NSCLC in routine practice in Japan. METHODS: This study used an electronic health records-based database of health claims and Diagnosis Procedure Combination data from 215 consenting hospitals in Japan. Records from April 2008 to September 2015 were analyzed...
May 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28493811/pooled-analysis-of-individual-patient-data-on-concurrent-chemoradiotherapy-for-stage-iii-non-small-cell-lung-cancer-in-elderly-patients-compared-with-younger-patients-who-participated-in-us-national-cancer-institute-cooperative-group-studies
#9
Thomas E Stinchcombe, Ying Zhang, Everett E Vokes, Joan H Schiller, Jeffrey D Bradley, Karen Kelly, Walter J Curran, Steven E Schild, Benjamin Movsas, Gerald Clamon, Ramaswamy Govindan, George R Blumenschein, Mark A Socinski, Neal E Ready, Wallace L Akerley, Harvey J Cohen, Herbert H Pang, Xiaofei Wang
Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non-small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients and Methods Individual patient data were collected from 16 phase II or III trials conducted by US National Cancer Institute-supported cooperative groups of concurrent chemoradiotherapy alone or with consolidation or induction chemotherapy for stage III non-small-cell lung cancer from 1990 to 2012...
May 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28456908/use-of-prophylactic-growth-factors-and-antimicrobials-in-elderly-patients-with-cancer-a-review-of-the-medicare-database
#10
Romina Sosa, Shuling Li, Julia T Molony, Jiannong Liu, Scott Stryker, Allan J Collins
PURPOSE: Growth factors and antimicrobials can reduce complications of chemotherapy-induced myelosuppression. Their prophylactic use in elderly patients is important given the associated comorbidity in this age group. There is a developing trend by payers to include supportive care agents in chemotherapy care bundles, which could affect clinical practice. We examined whether the febrile neutropenia (FN) risk categories can be used to describe utilization in the Centers for Medicare & Medicaid fee-for-service system in older adults...
April 29, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28451422/erlotinib-as-second-or-third-line-treatment-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-keio-lung-oncology-group-study-001-klog001
#11
Masayoshi Miyawaki, Katsuhiko Naoki, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Takashi Sato, Shinnosuke Ikemura, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Ho Namkoong, Kengo Otsuka, Masaki Miyazaki, Tetsuo Tani, Aoi Kuroda, Makoto Nishino, Hiroyuki Yasuda, Ichiro Kawada, Hidefumi Koh, Morio Nakamura, Takeshi Terashima, Fumio Sakamaki, Koichi Sayama, Tomoko Betsuyaku, Kenzo Soejima
The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II trial were aged ≥70 years, had stage III/IV or recurrent NSCLC, and had previously received 1 or 2 chemotherapy regimens that did not include EGFR-TKIs. The patients received erlotinib at a dose of 150 mg/day. The primary endpoint was overall response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and toxicity...
March 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28416124/assessment-of-the-external-validity-of-the-national-comprehensive-cancer-network-and-european-society-for-medical-oncology-guidelines-for-non-small-cell-lung-cancer-in-a-population-of-patients-aged-80-years-and-older
#12
REVIEW
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Non-small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented in clinical trials. This challenges the external validity of the evidence base for its management and of current guidelines, that we evaluated in a population of older patients. We retrieved randomized clinical trials (RCTs) supporting the guidelines and identified 18 relevant topics. We matched a cohort of NSCLC patients aged older than 80 years from the Moffitt Cancer Center database with the studies' eligibility criteria to check their qualification for at least 2 studies...
March 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28389722/undertreatment-trend-in-elderly-lung-cancer-patients-in-brazil
#13
Guilherme Jorge Costa, Maria Júlia Gonçalves de Mello, Carlos Gil Ferreira, Luiz Claudio Santos Thuler
PURPOSE: Elderly patients with lung cancer tend to be undertreated in comparison to younger patients. The objective of this study is to compare treatment modalities offered to lung cancer patients from 70 years of age or more with patients under 70. METHODS: For this study, an analytical cross-sectional epidemiological study conducted with data from the Brazilian hospital-based cancer registries between the years 2000 and 2011. In addition, odds ratios (OR) were calculated, with a 95% confidence intervals (95% CI), in conjunction with the construction of a logistic regression model...
April 7, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28366580/influence-of-age-on-guideline-concordant-cancer-care-for-elderly-patients-in-the-united-states
#14
Penny Fang, Weiguo He, Daniel R Gomez, Karen E Hoffman, Benjamin D Smith, Sharon H Giordano, Reshma Jagsi, Grace L Smith
PURPOSE: To examine the frequency of guideline-concordant cancer care in elderly patients, including "older" elderly (age ≥80 years). METHODS AND MATERIALS: Using the Surveillance, Epidemiology and End Results-Medicare dataset in patients aged ≥66 years diagnosed with nonmetastatic breast cancer (n=55,094), non-small cell lung (NSCLC) (n=36,203), or prostate cancer (n=86,544) from 2006 to 2011, chemotherapy, surgery, and radiation (RT) treatments were identified using claims...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28366575/timed-get-up-and-go-test-and-geriatric-8-scores-and-the-association-with-chemo-radiation-therapy-noncompliance-and-acute-toxicity-in%C3%A2-elderly-cancer-patients
#15
Judith G Middelburg, Mirjam E Mast, Maaike de Kroon, Jan J Jobsen, Tom Rozema, Huub Maas, Elizabet A Baartman, Debby Geijsen, Annija H van der Leest, Desirée J van den Bongard, Judith van Loon, Tom Budiharto, Jan Willem Coebergh, Mieke J Aarts, Henk Struikmans
PURPOSE: To investigate whether the Geriatric 8 (G8) and the Timed Get Up and Go Test (TGUGT) and clinical and demographic patient characteristics were associated with acute toxicity of radiation therapy and noncompliance in elderly cancer patients being irradiated with curative intent. METHODS AND MATERIALS: Patients were eligible if aged ≥65 years and diagnosed with breast, non-small cell lung, prostate, head and neck, rectal, or esophageal cancer, and were referred for curative radiation therapy...
January 29, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28341958/randomized-phase-ii-study-comparing-weekly-docetaxel-cisplatin-vs-gemcitabine-cisplatin-in-elderly-or-poor-performance-status-patients-with-advanced-non-small-cell-lung-cancer
#16
RANDOMIZED CONTROLLED TRIAL
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
BACKGROUND: Docetaxel/cisplatin (DP) and gemcitabine/cisplatin (GP) are standard treatment regimens for advanced non-small cell lung cancer (NSCLC). In spite of potent efficacy, the conventional 1-day DP is regarded as having more toxicity as compared with GP. There is increasing interest in a biweekly split administration of DP to reduce its toxicity. Hypothesis was that first-line biweekly DP is as safe as GP in the elderly or poor performance status (PS) patients. METHODS: Chemotherapy-naïve patients with advanced NSCLC (IIIB/IV) who were elderly (65<) or PS (ECOG 2) were randomized to DP or GP arm by balancing for ECOG (0-1 vs...
May 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28326834/thoracic-radiation-therapy-could-give-survival-benefit-to-elderly-patients-with-extensive-stage-small-cell-lung-cancer
#17
Changchun An, Wang Jing, Yan Zhang, Sujing Liu, Haiyong Wang, Kunli Zhu, Li Kong, Hongbo Guo, Hui Zhu
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28296721/single-pemetrexed-is-noninferior-to-platinum-based-pemetrexed-doublet-as-first-line-treatment-on-elderly-chinese-patients-with-advanced-nonsquamous-nonsmall-cell-lung-cancer
#18
COMPARATIVE STUDY
Xiaolin Pu, Wei Li, Binbin Lu, Zhaoxia Wang, Min Yang, Weifei Fan, Lijuan Meng, Zhigang Lv, Yuchun Xie, Jun Wang
BACKGROUND: To evaluate the clinical efficacy and toxicity of single pemetrexed treatment compared with platinum-based pemetrexed doublet pemetrexed-based as first-line treatment for advanced nonsquamous nonsmall cell lung cancer (NS-NSCLC) in elderly Chinese patients. METHODS: The study retrospectively reviewed 175 elderly Chinese patients with NS-NSCLC from June 2010 to September 2013: 90 patients received single pemetrexed treatment, 45 received pemetrexed plus oxaliplatin, and 40 received pemetrexed plus carboplatin...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28276698/the-role-of-checkpoint-inhibitors-immunotherapy-in-advanced-non-small-cell-lung-cancer-in-the-elderly
#19
Assunta Sgambato, Francesca Casaluce, Cesare Gridelli
Immune checkpoint inhibition is a novel treatment modality that has brought a new hope to patients with advanced NSCLC. Several molecules targeting cytotoxic T-lymphocyte antigen 4 (CTLA4) or programmed cell death 1 receptor/programmed death ligand-1 (PD1/PD-L1) pathways are under evaluation in NSCLC and three of them are currently approved: nivolumab and atezolizumab for advanced NSCLC after prior chemotherapy and pembrolizumab for advanced NSCLC expressing PD-L1 ≥ 1% after at least one prior chemotherapy regimen and > 50% as a first-line response...
February 20, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28191295/small-cell-carcinoma-of-the-prostate-in-an-elderly-patient-a-case-report-and-review-of-the-literature
#20
Dale Alan Whitaker, Daniel H Miller, Niveditha Jagadesh, Gerald W Strong, Lauren Hintenlang, William B Schenk, Gregory A Broderick, Katherine S Tzou, Steven J Buskirk
Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy...
November 17, 2016: Rare Tumors
keyword
keyword
109146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"